David J Yvars Group Has $75,000 Stock Holdings in Neuronetics, Inc. (NASDAQ:STIM)

David J Yvars Group raised its position in Neuronetics, Inc. (NASDAQ:STIM) by 47.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,325 shares of the company’s stock after buying an additional 14,825 shares during the period. David J Yvars Group’s holdings in Neuronetics were worth $75,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in STIM. First Washington CORP boosted its holdings in shares of Neuronetics by 88.8% in the 2nd quarter. First Washington CORP now owns 1,274,540 shares of the company’s stock worth $2,294,000 after acquiring an additional 599,455 shares in the last quarter. First Eagle Investment Management LLC boosted its stake in Neuronetics by 33.4% in the second quarter. First Eagle Investment Management LLC now owns 1,039,009 shares of the company’s stock worth $1,870,000 after purchasing an additional 260,000 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Neuronetics by 23.7% during the second quarter. Acadian Asset Management LLC now owns 326,975 shares of the company’s stock worth $587,000 after purchasing an additional 62,628 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Neuronetics by 124.5% in the second quarter. Renaissance Technologies LLC now owns 322,200 shares of the company’s stock valued at $580,000 after buying an additional 178,700 shares in the last quarter. Finally, HighTower Advisors LLC raised its holdings in shares of Neuronetics by 55.5% in the third quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock valued at $187,000 after buying an additional 87,816 shares during the last quarter. 53.59% of the stock is owned by institutional investors.

Neuronetics Stock Up 36.8 %

Shares of NASDAQ:STIM opened at $2.34 on Tuesday. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. The firm has a market cap of $71.01 million, a P/E ratio of -1.90 and a beta of 2.11. Neuronetics, Inc. has a 12 month low of $0.52 and a 12 month high of $5.07. The company’s 50-day moving average price is $1.18 and its two-hundred day moving average price is $1.21.

Neuronetics Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.